Blood pressure drug linked to death risk, study says
A well-known drug used to control blood pressure and angina has been linked to out-of-hospital heart failure, a new study says. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 18, 2019 Category: Consumer Health News Source Type: news

ACC 2019 Roundup: Abiomed Impella RP post-market study shows benefit in select patient group
Abiomed (NSDQ:ABMD) today released 18-month post-approval study data from patients treated with its Impella RP, touting a benefit to survival for specifically selected “Recover Right” protocol patients. Results from the study were presented at the American College of Cardiology’s 68th Annual Scientific Sessions in New Orleans, the Danvers, Mass.-based company said. The review follows a release posted by the FDA last month warning of a 17.4% survival rate with the Impella RP heart pump system, approximately 55% lower than the rate noted in the premarket study of the device. Abiomed said that it met wi...
Source: Mass Device - March 18, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Featured Patient Monitoring Replacement Heart Valves Abbott Abiomed Medtronic Source Type: news

ACC 2019: Abbott touts reduced stroke, bleeding and pump-clotting in HeartMate 3 trial
Abbott (NYSE:ABT) yesterday presented data from a new trial of its HeartMate 3 left ventricular assist device, touting a reduced rate of strokes, pump-related blood clots and bleeding episodes at two years as compared with the previous generation HeartMate II. Data in the trial was presented at the American College of Cardiology’s 68th Annual Scientific Session 2019 in New Orleans and published simultaneously in the New England Journal of Medicine, the Chicago-area medical device company said. Abbott touted its HeartMate 3 as the first implantable mechanical pump using fully magnetic levitation technology, makin...
Source: Mass Device - March 18, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Featured Abbott Source Type: news

8 Science-Backed Ways to Prevent Heart Attacks, According to New Guidelines
Experts have issued a new set of guidelines on the best ways to prevent first heart attacks, strokes and heart failure — and for the first time, they focus squarely on the patient. The new guidelines recognize how doctors can support people to not only address their medical risk factors, but also to change their behaviors and lifestyles in order to reduce their risk. The latest revisions to the guidelines, issued by the American College of Cardiology (ACC) and the American Heart Association (AHA), were announced at the annual meeting of the ACC. They are intended to help doctors figure out a patient’s risk of h...
Source: TIME: Health - March 18, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Heart Disease Source Type: news

ACC 2019: Medtronic, Edwards low-risk TAVR trial data could pave way to new indications
Results from trials of both Medtronic‘s (NYSE:MDT) and Edwards Lifesciences‘ (NYSE:EW) transcatheter aortic valve replacement systems exploring their use in low-risk patients indicated that the devices were as safe as open surgery, paving the way for possible new indications for TAVR technology. Data from the trials were presented over the weekend at the American College of Cardiology 68th Annual Scientific Session 2019 in New Orleans and simultaneously published in the New England Journal of Medicine. Currently, TAVR devices are only approved by the FDA for treating severe aortic valve stenosis in patients at ...
Source: Mass Device - March 18, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Featured Replacement Heart Valves Edwards Lifesciences Medtronic Source Type: news

Hopeful Heart: Team Care for Mood Plus HF Improves Wellbeing Hopeful Heart: Team Care for Mood Plus HF Improves Wellbeing
There is hope for improving mood and quality of life for heart failure patients with depression, a new trial suggests. Two-pronged care by a nurse care manager plus a diverse team topped usual care.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 18, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Diabetes drug effective against heart failure in wide spectrum of patients
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are especially pronounced in those with reduced ejection fraction, a measure of the heart's pumping ability indicative of poor heart functioning, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. (Source: World Pharma News)
Source: World Pharma News - March 18, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

More blood pressure drugs recalled over potential cancer risk
Another 43 lots of the blood pressure and heart failure drug Losartan have been recalled over the detection of a possible carcinogen in the tablets. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 17, 2019 Category: Consumer Health News Source Type: news

New cardiac pump clinically superior, safer for patients
(Brigham and Women's Hospital) The study of more than 1,000 patients with severe heart failure not only confirms that the HeartMate 3 ™ , a next-generation LVAD device, markedly reduced the need for re-operations due to pump malfunctions, but also found that it lowered risk of bleeding events and strokes, compared to the HeartMate II ™ . (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 17, 2019 Category: International Medicine & Public Health Source Type: news

Key to successful care of pregnant women in heart failure? Team-based care, study finds
(Intermountain Medical Center) Any time a pregnant woman presents in heart failure there are risks to both mother and baby. What does it take to protect the mother and her growing baby for the best possible outcome? According to clinicians at Intermountain Healthcare in Salt Lake City, the key to survival is a multidisciplinary team-based approach, involving cardiac and maternal/fetal/newborn specialists -- who normally don't work together -- to team up to successfully save mom and baby. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 16, 2019 Category: International Medicine & Public Health Source Type: news

Lung ultrasound beats chest x-ray for heart failure detection
Point-of-care lung ultrasound has a higher sensitivity than chest x-ray for...Read more on AuntMinnie.comRelated Reading: Lung ultrasound a practical tool for disease diagnosis Ultrasound finds more pneumonia than x-ray Ultrasound elevates diagnosis of pulmonary embolism AIUM: Lung US can handle diagnosis of pediatric pneumonia (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 15, 2019 Category: Radiology Source Type: news

How Your Blood Donation Can Help Save Lives
Every day, volunteer blood and platelet donors across the country are needed to help save lives. Eligible individuals can feel good knowing that by donating through the Red Cross, they ... The post... {This is a content summary only. Click the blog post title to continue reading this post, share your comments, browse the blog and more!} (Source: Red Cross Chat)
Source: Red Cross Chat - March 15, 2019 Category: International Medicine & Public Health Authors: American Red Cross Tags: Blood blood donation congestive heart failure heart pump heart transplant LVAD platelets Vikas Mahajan Source Type: news

MitraClip Device Approved for Patients With Secondary Mitral Regurgitation
FRIDAY, March 15, 2019 -- A new indication has been approved for the MitraClip Clip Delivery System in patients with normal mitral valves who develop heart failure symptoms and secondary or functional mitral regurgitation despite treatment with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 15, 2019 Category: Pharmaceuticals Source Type: news

Medical News Today: Heart failure: New drug could halt disease and improve heart function
A molecule that stops two proteins from interacting and impairing heart function halted heart failure and improved heart pumping capacity in rats. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 15, 2019 Category: Consumer Health News Tags: Heart Disease Source Type: news

Study: 3+ Eggs A Day Increases Risk Of Heart Disease, Early Death
(CNN) — It’s been debated for years: Are eggs good or bad for you? People who eat three or four eggs a day — or any equivalent of 300 mg of dietary cholesterol — have a higher risk of both heart disease and early death compared to those who eat fewer eggs, new research finds. “Eggs, especially the yolk, are a major source of dietary cholesterol,” wrote Victor Zhong, lead author and a postdoctoral fellow in the Department of Preventive Medicine at Northwestern University Feinberg School of Medicine in Chicago. In a study published Friday in the medical journal JAMA, he and his colleagues ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 15, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Eggs Source Type: news

Every Little Move You Make Can Help Your Health, Study Says
Lovers of vigorous exercise aren’t the only ones who get health benefits from physical activity. Lower-key workouts — even activities you’d never think of as exercise — can also improve your well-being, studies find. Now, new research published in JAMA Network Open shows just how impactful any type of movement can be. Compared to women who get less exercise, those who get lots of light physical activity may have up to a 42% lower risk of dying from coronary problems, such as heart attacks, and a 22% lower risk of developing cardiovascular disease, the study says. Light activity includes “most...
Source: TIME: Health - March 15, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Exercise/Fitness Longevity Source Type: news

Biotronik wins FDA nod for Acticor, Rivacor high-voltage tachycardia devices
Biotronik said yesterday it won FDA approval for its Acticor and Rivacor high-voltage cardiac rhythm management devices intended for treating patients with cardiac arrhythmias. The clearance covers the Berlin, Germany based company’s Rivacor VR-T, Rivacor DR-T, Rivacor HF-T QP, Acticor DX, Acticor CRT-DX Bipolar and Acticor CRT-DX devices. “When determining the best treatment plan for each patient, we assess individual needs and select a device system that provides optimal therapy programming with critical diagnostic features. We are often forced to choose between important features, which could compromise opti...
Source: Mass Device - March 15, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Featured Food & Drug Administration (FDA) Regulatory/Compliance Biotronik Source Type: news

Abbott Wins Additional Indication for MitraClip
Abbott Laboratories has received an expanded indication for MitraClip. The Abbott Park, IL-based company’s new indication addresses the secondary form of mitral regurgitation and significantly increases the amount of people with MR able to be treated with MitraClip. Based on this approval, Abbott said it will now begin discussions with the Center for Medicare and Medicaid Services (CMS) and physician specialty societies to request a revision to the national coverage determination that would expand Medicare coverage to include secondary MR patients.The indication was supported by the results of the COAPT T...
Source: MDDI - March 15, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news

Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
At the Annual Meeting of the Global Chagas Disease Coalition in Barcelona, Spain, Novartis announced that it is joining the Coalition as a member contributor. In addition, the company announced its commitment to launch a multinational, prospective, randomized study with heart failure drug, Entresto® (sacubitril / valsartan), in people with chronic Chagas cardiomyopathy, one form of heart failure with reduced ejection fraction. (Source: World Pharma News)
Source: World Pharma News - March 15, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

HIV Increases the Risk of Incident Heart Failure HIV Increases the Risk of Incident Heart Failure
Might HIV infection contribute to the subsequent development of heart failure? A new study investigates.JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 15, 2019 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

AHA News: Two Young Moms Bond Over Heart Failure, Transplant Experiences
Title: AHA News: Two Young Moms Bond Over Heart Failure, Transplant ExperiencesCategory: Health NewsCreated: 3/14/2019 12:00:00 AMLast Editorial Review: 3/15/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - March 15, 2019 Category: Cardiology Source Type: news

Light physical activity linked to lower risk of heart disease in older women
(NIH/National Heart, Lung and Blood Institute) Light physical activity such as gardening, strolling through a park, and folding clothes might be enough to significantly lower the risk of cardiovascular disease among women 63 and older, a new study has found. This kind of activity, researchers said, appears to reduce the risk of cardiovascular disease events such as stroke or heart failure by up to 22 percent, and the risk of heart attack or coronary death, by as much as 42 percent. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 15, 2019 Category: International Medicine & Public Health Source Type: news

MitraClip Valve Repair Device Gets Expanded Indication MitraClip Valve Repair Device Gets Expanded Indication
The FDA has approved the MitraClip for use in patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation.FDA Approvals (Source: Medscape Med Students Headlines)
Source: Medscape Med Students Headlines - March 14, 2019 Category: Universities & Medical Training Tags: Cardiology News Source Type: news

Philips touts adaptive servo ventilation sleep apnea study data
Royal Philips (NYSE:PHG) yesterday released results from a study exploring the use of adaptive servo ventilation in treating patients with complex sleep apnea. Results from the study were published in the American Journal of Respiratory and Critical Care Medicine, the Amsterdam-based company said. Investigators in the study compared the performance of four different ASV devices, including Philips’ DreamStation BiPap autoSV, as well as an ASV device originally associated with greater mortality during the SERVE-HF trial published in 2015, the company said. “The pursuit for scientific understanding of various...
Source: Mass Device - March 14, 2019 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Respiratory Royal Philips Source Type: news

Abbott Receives FDA Approval for Expanded Indication for MitraClip ™ Device
- The world's first minimally invasive mitral valve repair device now approved to help difficult-to-treat heart failure patients with clinically significant secondary mitral regurgitation (Source: Abbott.com)
Source: Abbott.com - March 14, 2019 Category: Pharmaceuticals Source Type: news

Abbott wins expanded indications for MitraClip
The FDA today said that it granted Abbott (NYSE:ABT) a new indication for its MitraClip system, expanding coverage of the device to patients with normal mitral valves with diminished left heart function. The indication expands upon the original approval, which the Chicago-area medical device maker won in 2013, clearing it for use in reducing mitral regurgitation in patients with mitral valve abnormalities whose risks for mitral valve surgery were prohibitive. With its new clearance, the MitraClip is cleared for use for patients with normal mitral valves who develop heart failure symptoms and moderate-to-severe or...
Source: Mass Device - March 14, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Featured Food & Drug Administration (FDA) Regulatory/Compliance Abbott Source Type: news

FDA Approves New Indication for Valve Repair Device to Treat Certain Heart Failure Patients with Mitral Regurgitation
SILVER SPRING, Md., March 14, 2019 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration today approved a new indication for a heart valve repair device that is intended to reduce moderate-to-severe or severe mitral regurgitat... Devices, Interventional, Cardiology, FDA Abbott Vascular, MitraClip, mitral valve, mitral regurgitation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 14, 2019 Category: Pharmaceuticals Source Type: news

FDA approves new indication for valve repair device to treat certain heart failure patients with mitral regurgitation
Device is for treatment of patients to reduce mitral regurgitation in certain patients with heart failure symptoms who fail to respond to traditional therapy (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 14, 2019 Category: American Health Source Type: news

AHA News: Two Young Moms Bond Over Heart Failure, Transplant Experiences
THURSDAY, March 14, 2019 (American Heart Association News) -- Sarah Bradley's second pregnancy was uneventful until 30 weeks, when she found herself swollen, breathless and unusually fatigued. When her chest and left side also began to hurt a few... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 14, 2019 Category: General Medicine Source Type: news

FDA Approves New Generic Valsartan to Ease Shortage
WEDNESDAY, March 13, 2019 -- The U.S. Food and Drug Administration on Tuesday approved a new generic version of the high blood pressure/heart failure drug valsartan, saying the move might help ease the current medication shortage. The agency said it... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 13, 2019 Category: Pharmaceuticals Source Type: news

FDA OKs a New Generic of the Blood Pressure Drug Valsartan to Ease Shortage Due to Recalls
WEDNESDAY, March 13, 2019 -- The U.S. Food and Drug Administration on Tuesday approved a new generic version of the high blood pressure/heart failure drug valsartan, saying the move might help ease the current medication shortage. The agency said... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 13, 2019 Category: General Medicine Source Type: news

FDA Fast-Tracks Approval of Generic Valsartan FDA Fast-Tracks Approval of Generic Valsartan
Amid ongoing tainted sartan drug recalls, the US Food and Drug Administration has approved a new generic of valsartan (Diovan) to treat hypertension and heart failure.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 13, 2019 Category: Neurology Tags: Cardiology News Alert Source Type: news

FDA approves a new generic valsartan
Today, the U.S. Food and Drug Administration approved a new generic of Diovan (valsartan). Valsartan is an angiotensin II receptor blocker (ARB) that treats high blood pressure and heart failure. The FDA prioritized the review of this drug application to help relieve the recent shortage of this critical medicine (Source: World Pharma News)
Source: World Pharma News - March 12, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves a New Generic Diovan (valsartan)
March 12, 2019 -- Today, the U.S. Food and Drug Administration approved a new generic of Diovan (valsartan). Valsartan is an angiotensin II receptor blocker (ARB) that treats high blood pressure and heart failure. The FDA prioritized the review of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 12, 2019 Category: Pharmaceuticals Source Type: news

William T. Abraham, MD, joins V-Wave as Chief Medical Officer
CAESAREA, Israel, March 12, 2019 -- (Healthcare Sales & Marketing Network) -- V-Wave Ltd., an early stage medtech company developing an implantable interatrial shunt device for treating advanced heart failure (HF) and pulmonary arterial hypertension (PAH)... Devices, Cardiology, Personnel V-Wave, interatrial shunt, heart failure, pulmonary arterial hypertension (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 12, 2019 Category: Pharmaceuticals Source Type: news

Endogenous Testosterone Tied to Higher Heart Disease Risks (CME/CE)
(MedPage Today) -- Endogenous testosterone could be a modifiable risk factor for thromboembolism and heart failure (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 11, 2019 Category: Cardiology Source Type: news

Edwards Makes Significant Moves in the Mitral Valve Space
Edwards Lifesciences bolstered its presence in the mitral valve space through a pair of transactions it announced Monday. The Irvine, CA based company invested $35 million in an exclusive right to acquire Corvia Medical and in addition the firm obtained certain assets of Mitralign for an undisclosed sum. Edwards investments come on the heels of Boston Scientific exercising its option to acquire the remaining shares of Millipede Inc. for $325 million. In addition, the Marlborough, MA-based company said a $125 million payment becoming available upon achievement of a commercial milestone. Tewksbury, MA-based Corvia Medical&ac...
Source: MDDI - March 11, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news

Edwards Lifesciences gets in on Corvia, Mitralign
Edwards Lifesciences (NYSE:EW) said today that it made a pair of strategic bets on the structural heart space, paying $35 million for the right to acquire Corvia Medical and paying an unspecified amount for some of mitral valve repair device maker Mitralign‘s assets. Tewksbury, Mass.-based Corvia is developing an interatrial shunt to treat heart failure by creating a small opening between the left and right atria to lower blood pressure in the left atrium and lungs. The device has CE Mark approval in the European Union and a pivotal U.S trial aimed at winning a nod from the FDA is under way, Edwards said. &ldquo...
Source: Mass Device - March 11, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Implants Featured Mergers & Acquisitions Replacement Heart Valves Edwards Lifesciences Source Type: news

Mar 8 2019 This Week in Cardiology Mar 8 2019 This Week in Cardiology
N of 1 hypertension trials, heart failure readmissions and HRRP, insulin, CTA vs functional stress testing, and the ongoing paclitaxel PAD controversy are discussed in this week ’ s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 8, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news

'Revolutionary' heart attack drug could reduce tissue damage by up to 60%
Researchers led by Imperial College London found they could reduce lasting damage after a heart attack which could help doctors tackle heart failure, a condition caused by sections of tissue dying. (Source: the Mail online | Health)
Source: the Mail online | Health - March 8, 2019 Category: Consumer Health News Source Type: news

Endogenous Testosterone Linked to Cardiovascular Disease
THURSDAY, March 7, 2019 -- In men, endogenous testosterone may have a causal role in thromboembolism, heart failure, and myocardial infarction, according to a study published online March 6 in The BMJ. Shan Luo, from the University of Hong Kong, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 7, 2019 Category: Pharmaceuticals Source Type: news

High Testosterone Levels Are Bad News for the Heart
THURSDAY, March 7, 2019 -- High testosterone levels can drastically increase a man's risk of heart failure and stroke-causing blood clots, a new study reports. Men with a genetic predisposition to high testosterone levels have a nearly eightfold... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 7, 2019 Category: General Medicine Source Type: news

High testosterone levels could be killing men by causing blood clots and heart failure, study claims
A joint study by the City University of New York and the University of Hong Kong examined relations between the killer heart conditions and the male sex hormone. (Source: the Mail online | Health)
Source: the Mail online | Health - March 7, 2019 Category: Consumer Health News Source Type: news

Testosterone linked to higher risk of heart disease, research finds
Study that analysed data from UK found men were more likely to develop heart conditionsMen might be at greater risk of developing heart failure, heart attacks or blood clots than women at least in part because they have higher levels of testosterone, scientists say.The team said the finding could help in the development of new treatments for heart disease.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - March 7, 2019 Category: Science Authors: Nicola Davis Tags: Heart disease Heart attack Health Society Science Men's health & wellbeing Source Type: news

Financial Penalties Curb All Readmissions in HF Patients Financial Penalties Curb All Readmissions in HF Patients
In a retrospective study of almost 13 million Medicare heart failure hospitalizations, 30-day readmission rules were associated with small reductions in readmission for other conditions in HF patients.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 5, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Blood pressure medication recall expands again to include losartan
A widespread recall of common blood pressure and heart failure medications has been expanded to include more drugs containing losartan. The recall is due to an "impurity" that is classified as a potential human carcinogen. (Source: CNN.com - Health)
Source: CNN.com - Health - March 4, 2019 Category: Consumer Health News Source Type: news

UA researcher seeks to prevent heart failure after a heart attack
(University of Arizona Health Sciences) American Heart Association funding will allow UA College of Medicine -- Phoenix post-doctoral fellow to target fibroblasts. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 4, 2019 Category: International Medicine & Public Health Source Type: news

Ask Dr Ellie: Can a herb diet help my heart?  
DR ELLIE CANNON: With age, aortic valve disease is common, as a build-up of calcium prevents it opening and closing. Both types of aortic valve disease can lead to life-limiting heart failure. (Source: the Mail online | Health)
Source: the Mail online | Health - March 2, 2019 Category: Consumer Health News Source Type: news

Blood Pressure Medication Recall Expands Again To Include Losartan
(CNN) — A widespread recall of common blood pressure and heart failure medications has been expanded to include more drugs containing losartan. The recall is due to an “impurity” that is classified as a potential human carcinogen. The impurity, N-Nitroso-N-methyl-4-aminobutyric acid or NMBA, is also classified as a known animal carcinogen, the US Food And Drug Administration noted in a news release about the recall Friday. Camber Pharmaceuticals Inc. voluntarily recalled 87 lots of losartan tablets in the United States on Thursday. The recalled tablets, made by Hetero Labs Ltd. In India and distributed by...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 1, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Consumer Health News FDA losartan Valsartan Source Type: news

High-fat diet and age alter microflora and cause inflammation in heart failure
(University of Alabama at Birmingham) Growing older and a high-fat diet enriched with omega 6 fatty acids are major contributors to health risks ranging from diabetes to heart failure. How these factors regulate the immune response is now described -- a calorie-dense, obesity-generating diet in aging mice disrupts the composition of the gut microbiome. This correlates with development of a system-wide nonresolving inflammation in acute heart failure, with a notable disruption of the immune cell profile, primarily the neutrophil-leukocyte ratio. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 1, 2019 Category: International Medicine & Public Health Source Type: news